U.S. FDA Approves ThromboGenics’ JETREA® (Ocriplasmin)

News   Oct 18, 2012

 
U.S. FDA Approves ThromboGenics’ JETREA® (Ocriplasmin)
 
 
 

RELATED ARTICLES

Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth

News

Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

READ MORE

Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B Treatment

News

All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.

READ MORE

Cannabinoids Are Easier on the Brain Than Booze, Study Finds

News

The research was published in the journal Addiction.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE